Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Blogs, Rare diseases
Orphan drugs: How to avoid costly stock losses in Europe
Blogs, Rare diseases
Out-licensing vs partnering: Strategies for accessing Europe
Blogs, Rare diseases
Compassionate use programs in Europe: all you need to know
Blogs, Rare diseases
Is data drought holding back your orphan drug?
Thought Leadership, Rare diseases
Market access for orphan drugs in Switzerland: a guide for US Biotechs
Blogs, Rare diseases
An introduction to PASS studies
Thought Leadership, Rare diseases
The impact of real-world data in gaining access to the European orphan drugs market.
Thought Leadership, Rare diseases
Navigating early access in Europe: a strategic blueprint for biotech leaders
Blogs, Rare diseases
Early access programs – benefits, challenges and the Sciensus solution